Nutex Health Inc. — Deeply Undervalued Healthcare Services And Technology Company

As part of our ongoing series at The Acquirer’s Multiple, each week we highlight a stock from our Stock Screeners that may represent an undervalued opportunity hiding in plain sight.

This week’s spotlight is Nutex Health Inc. (NUTX) — a healthcare services and technology company focused on micro-hospitals, hospital operations, and population health management solutions across the United States.

Despite investor concerns around healthcare reimbursement pressure, execution risk, and the company’s rapid expansion strategy, NUTX currently trades at valuation levels that may suggest the market is underestimating the improvement in its operating performance, cash generation, and scalability.

Business Overview

Nutex Health operates a hybrid healthcare model combining facility operations with cloud-based population health management technology. The company focuses on smaller, localized healthcare facilities designed to provide emergency and outpatient care more efficiently than traditional large hospital systems.

Core components of the business include:

✓ Micro-hospitals
✓ Emergency healthcare services
✓ Population health management
✓ Cloud-based healthcare platforms
✓ Hospital operational partnerships

The business benefits from growing healthcare demand, localized facility networks, and recurring patient engagement across its operating footprint.

What Is IV/P?

IV/P compares a conservative intrinsic valuation to the current market price.

IV/P > 1 = Undervalued
IV/P < 1 = Overvalued

NUTX’s IV/P = 1.70, suggesting the stock may be trading below conservative intrinsic value estimates.

Supporting Metrics

Revenue (TTM): $880M
Gross Profit: $418M
Operating Income: $276M
Net Income: $96M
Free Cash Flow: $269M

Acquirer’s Multiple (AM): 4.32

An AM near 4 places NUTX in deep value territory, particularly for a business that has recently demonstrated substantial operating leverage and improving profitability.

Revenue & Profitability

Recent financial results reflect dramatic improvement in operating performance as revenue growth and margin expansion accelerated.

Approximate margins:

• Gross Margin: 47%
• Operating Margin: 31%
• Net Margin: 11%

Diluted EPS (TTM): $13.67

These margins reflect:

• Rapid scaling of operations
• Improved healthcare facility utilization
• Higher-margin technology services
• Operating leverage
• Strong reimbursement collections

Unlike many speculative healthcare growth stories, Nutex is now producing meaningful operating income and free cash flow alongside expanding revenues.

Balance Sheet Position

Total Assets: $919M
Total Liabilities: $495M
Shareholders’ Equity: $423M
Total Debt: $351M
Cash & Equivalents: $186M

The balance sheet has strengthened considerably alongside rising profitability and cash generation.

Working Capital: $381M

This provides flexibility for expansion, debt management, and continued investment in healthcare infrastructure.

Cash Flow & Capital Efficiency

Operating Cash Flow: $273M
Free Cash Flow: $269M

This supports:

✓ Expansion opportunities
✓ Debt management
✓ Share repurchases
✓ Operational investment
✓ Financial flexibility

Because capital expenditure requirements remain relatively modest compared to cash generation, a large portion of earnings converts directly into free cash flow.

Why NUTX May Be Attractive

Market concerns include:

• Healthcare reimbursement uncertainty
• Regulatory risk
• Execution risk
• Volatile historical results
• Small-cap healthcare sentiment

However, fundamentals remain compelling:

• AM of 4.32 signals deep value
• IV/P of 1.70 suggests undervaluation
• Rapid revenue growth
• Strong operating leverage
• Significant free cash flow generation
• Improving balance sheet

Conclusion

With an IV/P of 1.70 and an Acquirer’s Multiple of 4.32, Nutex Health appears to be an intriguing deep-value opportunity in healthcare.

Its combination of rapidly improving profitability, strong cash generation, scalable healthcare infrastructure, and discounted valuation suggests the market may still be heavily discounting past uncertainty while underappreciating the company’s current earnings power and operational momentum.